These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10384860)

  • 1. The efficiency concept in pharmacodynamics.
    Alván G; Paintaud G; Wakelkamp M
    Clin Pharmacokinet; 1999 May; 36(5):375-89. PubMed ID: 10384860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diuretic effect and diuretic efficiency after intravenous dosage of frusemide.
    Alván G; Helleday L; Lindholm A; Sanz E; Villén T
    Br J Clin Pharmacol; 1990 Feb; 29(2):215-9. PubMed ID: 2306413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natriuretic efficiency of frusemide as a consequence of drug input rate.
    Wakelkamp M; Alván G; Paintaud G
    Br J Clin Pharmacol; 1997 May; 43(5):481-91. PubMed ID: 9159563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide.
    Wakelkamp M; Alván G; Paintaud G
    Br J Clin Pharmacol; 1998 Jan; 45(1):63-70. PubMed ID: 9489596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of drug input rate on the development of tolerance to frusemide.
    Wakelkamp M; Alván G; Scheinin H; Gabrielsson J
    Br J Clin Pharmacol; 1998 Nov; 46(5):479-87. PubMed ID: 9833602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.
    Klausner EA; Lavy E; Stepensky D; Cserepes E; Barta M; Friedman M; Hoffman A
    J Clin Pharmacol; 2003 Jul; 43(7):711-20. PubMed ID: 12856384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics and pharmacodynamics of torasemide.
    Knauf H; Mutschler E
    Clin Pharmacokinet; 1998 Jan; 34(1):1-24. PubMed ID: 9474471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
    Lesne M
    Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable furosemide absorption and poor predictability of response in elderly patients.
    Murray MD; Haag KM; Black PK; Hall SD; Brater DC
    Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Features of the pharmacodynamics and pharmacokinetics of furosemide upon long-term administration in rats].
    Briukhanov VM; Zverev IaF; Lampatov VV; Zharikov AIu
    Eksp Klin Farmakol; 2007; 70(2):33-6. PubMed ID: 17523448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.
    Ebling WF; Levy G
    Ann Pharmacother; 1996 Jan; 30(1):12-9. PubMed ID: 8773159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple comparison procedure and modeling: a versatile tool for evaluating dose-response relationships in veterinary pharmacology - a case study with furosemide.
    Bieth B; Bornkamp B; Toutain C; Garcia R; Mochel JP
    J Vet Pharmacol Ther; 2016 Dec; 39(6):539-546. PubMed ID: 27166146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of frusemide formulation on diuretic effect and efficiency.
    Wakelkamp M; Blechert A; Eriksson M; Gjellan K; Graffner C
    Br J Clin Pharmacol; 1999 Sep; 48(3):361-6. PubMed ID: 10510147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.
    Wakelkamp M; Alván G; Gabrielsson J; Paintaud G
    Clin Pharmacol Ther; 1996 Jul; 60(1):75-88. PubMed ID: 8689815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The validity of the sigmoid Emax model and efficiency concept in diuretic studies.
    Alván G; Hammarlund-Udenaes M; Odlind B
    Br J Clin Pharmacol; 1991 Feb; 31(2):210-1. PubMed ID: 2049241
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of Emax model in diuretic studies.
    Noormohamed FH
    Br J Clin Pharmacol; 1990 Dec; 30(6):907-8. PubMed ID: 2288838
    [No Abstract]   [Full Text] [Related]  

  • 18. Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters.
    Wolf-Coporda A; Lovrić Z; Huić M; Francetić I; Vrhovac B; Plavsić F; Skreblin M
    Int J Clin Pharmacol Res; 1996; 16(4-5):83-8. PubMed ID: 9172005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats.
    Ha HA; Lee SH; Kim SH; Kim ON; Lee MG
    Res Commun Mol Pathol Pharmacol; 1996 Jul; 93(1):109-28. PubMed ID: 8865375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection, quantification, and pharmacokinetics of furosemide and its effects on urinary specific gravity following IV administration to horses.
    Dirikolu L; Lehner AF; Hughes C; Karpiesiuk W; Camargo FC; Harkins JD; Woods WE; Bosken JM; Boyles J; Troppmann A; Fisher M; Tobin T
    Vet Ther; 2003; 4(4):350-63. PubMed ID: 15136977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.